StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Strong guidance reduction combined with a revenue miss triggered a sharp share decline to a new 52-week low; even with an EPS beat, the market focuses on slower growth in ATTR-CM and execution risk for nucrisiran, a difficult near-term sentiment shift seen in similar biotech earnings where guidance cuts negate upside from a beat.
What happened, with direct paths to the underlying reporting
Alnylam beat Q2 EPS estimates but missed revenue, trimming 2026 TTR sales guidance amid ATTR-CM market normalization. Amvuttra led product revenue; Onpattro contributions were modest, and nucrisiran progresses remain a key uncertainty. The stock fell to a 52-week low, signaling near-term downside unless trial data renews confidence.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.